Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Stomach Neoplasms 2Prostatic Neoplasms 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Ovarian Neoplasms 1Melanoma 1Locally Advanced Colorectal Cancer 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

pembrolizumab 243Carboplatin 211Pemetrexed 177Cisplatin 131Paclitaxel 113Nivolumab 101Docetaxel 87osimertinib 85durvalumab 78Specimen Handling 56atezolizumab 55Gemcitabine 52Drug Therapy 52Magnetic Resonance Spectroscopy 50Radiosurgery 48Radiotherapy 47Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 34Cetuximab 30tislelizumab 29amivantamab 22Taxes 22Platinum Compounds 20Blood Specimen Collection 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × SHR-1701 × 1 year × Clear all
NCT07175220 2025-11-18

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡